From the Food and Drug Administration.
Crawford
Lester M
LM
Deputy Commissioner, US Food and Drug Administration, Rockville, MD 20857, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003248:Constipation / Q000150:complications; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy*; D008297:Male; D016602:Needlestick Injuries / Q000453:epidemiology*; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D005765:Gastrointestinal Agents; D007211:Indoles; D009944:Organoplatinum Compounds; D017366:Serotonin Receptor Agonists; D000077150:Oxaliplatin; C105050:tegaserod